鼾眠Ⅰ号联合持续正压通气治疗阻塞性睡眠呼吸暂停低通气综合征临床研究  

Clinical Study of Hanmian ⅠCombined with Continuous Positive Airway Pressure for Obstructive Sleep Apnea Hypopnea Syndrome

作　　者：刘笑静[1] 李权[1] 杜单瑜[1] 郑正伟[1] 丰银平[1] 陈灵勇[1] 

机构地区：[1]丽水市中医院呼吸科,浙江丽水323000

出　　处：《新中医》2017年第11期28-31,共4页New Chinese Medicine

基　　金：丽水市科技局公益性技术应用研究项目(2014GYX008)

摘　　要：目的:观察鼾眠Ⅰ号联合持续正压通气治疗痰瘀互结型阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者的效果。方法:将64例痰瘀互结型OSAHS患者随机分为治疗组、对照组各32例。治疗组予鼾眠Ⅰ号联合持续正压通气治疗,对照组予持续正压通气治疗,2组疗程均为1月。观察治疗前后患者Epworth嗜睡量表(ESS)评分、呼吸暂停低通气指数(AHI)、呼吸紊乱指数(RDI)、最低血氧饱和度(LSa O2)以及血清C-反应蛋白(CRP)、白细胞介素-1(IL-1)、IL-6、IL-10、肿瘤坏死因子-α(TNF-α)的变化。结果:治疗后,2组ESS评分均较治疗前下降,差异均有统计学意义(P<0.01,P<0.05);治疗组ESS评分低于对照组,差异有统计学意义(P<0.05)。2组AHI、RDI均较治疗前下降,差异均有统计学意义(P<0.01,P<0.05)。治疗组治疗前后LSa O2比较,差异有统计学意义(P<0.05),2组治疗后LSa O2比较,差异有统计学意义(P<0.05)。治疗组CRP、IL-1、IL-6、TNF-α均较治疗前下降,IL-10较治疗前上升,差异均有统计学意义(P<0.01,P<0.05);对照组CRP、IL-6、TNF-α均较治疗前下降,差异均有统计学意义(P<0.05);2组CRP、IL-6、TNF-α比较,差异均有统计学意义(P<0.01,P<0.05)。结论:鼾眠Ⅰ号联合持续正压通气治疗OSAHS可改善患者白天的嗜睡程度,减少夜间睡眠呼吸暂停、低通气次数,改善RDI,作用机制可能与降低血清炎症因子水平、减轻炎症反应相关。Objective. To observe the effect of Hanmian I combined with continuous positive airway pressure for obstructive sleep apnea hypopnea syndrome（OSAHS） of phlegm and blood stasis type. Methods- Divided 64 cases of OSAHS patients of phlegm and blood stasis type into the treatment group and the control group randomly, 32 cases in each group. The treatment group was treated with Hanmian I combined with continuous positive airway pressure, while the control group was treated with continuous positive airway pressure. Both groups received treatment for one month. Observed changes of Epworth sleeping scale （ESS） score, apnea-hypopnea index（AHI）, respiratory disturbance index（RDI）, lowest oxygen saturation （LSaO2）, serum C-reactive protein （CRP）, interleukin-1 {IL-1）, intefleukin-6（lL-6）, interleukin-10（IL-10）, and tumor necrosis factor-α （TNF-5） in both groups. Results： After treatment, ESS scores in both groups were decreased when compared with those before treatment（P 〈 0.01, P 〈 0.05）, and ESS scores in the treatment group were lower than those in the control group（P 〈0.05）. After treatment, AHI and RDI in both groups were declined, comparing with those before treatment（P 〈 0.01, P 〈 0.05）. The comparison of LSaQ in the treatment group before and after treatment showed significance in the difference （P 〈0.05）. Compared LSaO2 in the two groups after treatment, the difference was significant （P 〈0.05）. Comparing with those before treatment, levels of CRP, IL-1, IL-6, and TNF-α in the treatment were declined, while levels of I L-10 in the treatment group were raised, differences being significant（P 〈 0.01, P 〈 0.05）. Comparing with those before treatment, levels of CRP, IL-6 and TNF-α in the control group were declined, dttterences being signmcamtr〈u.. Compared levels of CRP, I L-6 and TNF-a in the two groups, differences were all significant（P〈 0.01, P〈 0.05）. Conclusion： The therapy of Hanmian I combined with continuous posit

关 键 词：阻塞性睡眠呼吸暂停低通气综合征(OSAHS) 痰瘀互结证 中西医结合疗法 鼾眠Ⅰ号 持续正压通气(CPAP) Epworth嗜睡量表(ESS) 炎症因子 

分 类 号：R442.8[医药卫生—诊断学]